<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>miR-361-5p &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/mir-361-5p/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Thu, 27 Nov 2025 07:58:30 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>miR-361-5p &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Shikonin Targets ZEB1 via p53 and miR-361-5p</title>
		<link>https://bioengineer.org/shikonin-targets-zeb1-via-p53-and-mir-361-5p/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 27 Nov 2025 07:58:04 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[EMT Inhibition]]></category>
		<category><![CDATA[Glioblastoma treatment]]></category>
		<category><![CDATA[miR-361-5p]]></category>
		<category><![CDATA[p53 regulation]]></category>
		<category><![CDATA[Shikonin]]></category>
		<guid isPermaLink="false">https://bioengineer.org/shikonin-targets-zeb1-via-p53-and-mir-361-5p/</guid>

					<description><![CDATA[In a groundbreaking study, researchers have uncovered the remarkable potential of Shikonin, a natural compound derived from the roots of the medicinal herb Lithospermum erythrorhizon, in combatting the aggressive nature of glioblastoma cells. This research delves deeply into the mechanics of how Shikonin not only inhibits the epithelial-mesenchymal transition (EMT) but also plays a crucial [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">302139</post-id>	</item>
		<item>
		<title>Shikonin Blocks EMT in Glioblastoma via p53 Activation</title>
		<link>https://bioengineer.org/shikonin-blocks-emt-in-glioblastoma-via-p53-activation/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 07 Sep 2025 07:21:26 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Epithelial-mesenchymal transition inhibition]]></category>
		<category><![CDATA[Glioblastoma treatment]]></category>
		<category><![CDATA[miR-361-5p]]></category>
		<category><![CDATA[p53 activation]]></category>
		<category><![CDATA[Shikonin]]></category>
		<guid isPermaLink="false">https://bioengineer.org/shikonin-blocks-emt-in-glioblastoma-via-p53-activation/</guid>

					<description><![CDATA[Recent studies in the field of oncology have shed light on the complexities of glioblastoma, a highly aggressive brain tumor characterized by its rapid progression and poor prognosis. A breakthrough research article published in BMC Neuroscience highlights the role of Shikonin, a bioactive compound derived from the root of Lithospermum erythrorhizon, in the inhibition of [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">267323</post-id>	</item>
	</channel>
</rss>
